 The conditional marketing authorization pathway in Europe for crofelemer for this orphan disease is the initial focus of Napo EU under the license agreement between Napo EU and Napo Pharmaceuticals Jaguar to host investor webcast Monday, September 20th at 8:30 a.m. Eastern; Click here to register for webcast SAN FRANCISCO, CA ACCESSWIRE September 15, 2021 Jaguar Health NASDAQ:JAGX today announced that the European Medicines Agency EMA has confirmed that the Orphan Drug Designation ODD application for crofelemer submitted by Napo EU S.p.A. 